DR. JERROLD MICHAEL OLEFSKY, M.D.
Osteopathic Medicine in La Jolla, CA
License number
California G18567
Category
Osteopathic Medicine
Type
Internal Medicine
License number
California G18567
Category
Osteopathic Medicine
Type
Endocrinology, Diabetes & Metabolism
Address
Address
2
9500 Gilman Drive Ucsd, La Jolla, CA 92093
1237 Via Mil Cumbres, Solana Beach, CA 92075
1237 Via Mil Cumbres, Solana Beach, CA 92075
Phone
(858) 534-6651
(858) 534-6653 (Fax)
(858) 534-6653 (Fax)
Professional information
Jerrold Michael Olefsky, La Jolla CA
Specialties:
Endocrinologist
Address:
9500 Gilman Dr, La Jolla, CA 92093
Education:
University of Illinois, College of Medicine - Doctor of Medicine
Stanford Hospital & Clinics - Fellowship - Endocrinology, Diabetes, and Metabolism (Internal Medicine)
Proctor Hospital - Residency - Family Medicine
Stanford Hospital & Clinics - Fellowship - Endocrinology, Diabetes, and Metabolism (Internal Medicine)
Proctor Hospital - Residency - Family Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Endocrinology and Metabolism (Internal Medicine)
Dr. Jerrold M Olefsky, La Jolla CA - MD (Doctor of Medicine)
Specialties:
Endocrinology, Diabetes & Metabolism, Endocrinology & Metabolism
Address:
9500 Gilman Dr, La Jolla 92093
(858) 534-6651 (Phone), (858) 534-6653 (Fax)
San Diego Office
200 W Arbor Dr, San Diego 92103
(858) 657-7000 (Phone), (619) 543-3183 (Fax)
(858) 534-6651 (Phone), (858) 534-6653 (Fax)
San Diego Office
200 W Arbor Dr, San Diego 92103
(858) 657-7000 (Phone), (619) 543-3183 (Fax)
Certifications:
Diabetes, Metabolism & Endocrinology, 1975, Internal Medicine, 1975
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
9500 Gilman Dr, La Jolla 92093
San Diego Office
200 W Arbor Dr, San Diego 92103
UCSD Medical Center - Hillcrest
200 West Arbor Dr, San Diego 92103
San Diego Office
200 W Arbor Dr, San Diego 92103
UCSD Medical Center - Hillcrest
200 West Arbor Dr, San Diego 92103
Education:
Medical School
University of Illinois At Chicago / College of Medicine
Graduated: 1967
U Ill Rsch & Ed Hosps
Stanford University
University of Illinois At Chicago / College of Medicine
Graduated: 1967
U Ill Rsch & Ed Hosps
Stanford University
Jerrold Michael Olefsky, La Jolla CA
Specialties:
Internal Medicine, Endocrinology and Metabolism, Endocrinology, Diabetes & Metabolism
Work:
Ucsd Medical Group
9350 Campus Point Dr, La Jolla, CA 92037 Ucsd
9500 Gilman Dr, La Jolla, CA 92093
9350 Campus Point Dr, La Jolla, CA 92037 Ucsd
9500 Gilman Dr, La Jolla, CA 92093
Education:
University of Illinois at Chicago (1967)
Protein Kinase C Antagonist Related To Insulin Receptor
US Patent:
6511811, Jan 28, 2003
Filed:
Jun 7, 1995
Appl. No.:
08/485393
Inventors:
Jerrold M. Olefsky - Solana Beach CA
Tahir S. Pillay - San Diego CA
Tahir S. Pillay - San Diego CA
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
C07K 702
US Classification:
435 71, 435 72, 435183, 530300, 530326, 530327, 530350
Abstract:
Methods and compositions are provided for the treatment of insulin-resistance through the inhibition of protein kinase C-mediated phosphorylation of the amino acid residue Ser of the insulin receptor. Methods for testing candidate compounds suitable for inhibition of serine-phosphorylation by protein kinase C are also provided.
Use Of Thiazolidinedione Derivatives And Related Antihyperglycemic Agents In The Treatment Of Insulin Resistant Subjects With Normal Glucose Tolerance In Order To Prevent Or Delay The Onset Of Noninsulin-Dependent Mellitus
US Patent:
5708012, Jan 13, 1998
Filed:
Apr 28, 1995
Appl. No.:
8/431266
Inventors:
Jerrold M. Olefsky - Solana Beach CA
Assignee:
Sankyo Company, Limited - Tokyo
International Classification:
A01N 4340
US Classification:
514337
Abstract:
Novel methods of using thiazolidinone derivatives and related antihyperglycemic agents to treat populations exhibiting insulin resistent non-impaired glucose tolerance (IRNIGT) in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus (NIDDM) and complications arising therefrom are disclosed.
Methods Of Treating Inflammatory Conditions
US Patent:
2012029, Nov 22, 2012
Filed:
Jun 11, 2012
Appl. No.:
13/493241
Inventors:
Jerrold M. Olefsky - Solana Beach CA, US
Da Young Oh - La Jolla CA, US
Da Young Oh - La Jolla CA, US
Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA
International Classification:
A61K 31/202, C12N 15/113, C12N 5/071, A61P 29/00
US Classification:
514560, 536 245, 435375
Abstract:
The present invention provides methods of treating a β-arrestin2 mediated and/or GPR120 mediated response in a subject. The β-arrestin2 mediated and/or GPR120 mediated response can be inflammation, including diabetes, inflammation associated with obesity and obesity. The methods can comprise administering to a subject a therapeutically effective amount of a compound predicted to bind a β-arrestin2 molecule and/or GPR120, wherein the compound selectively activates a β-arrestin2-dependent signaling pathway of GPR120.
Method For Treatment Of Insulin Resistance
US Patent:
5726027, Mar 10, 1998
Filed:
Mar 8, 1996
Appl. No.:
8/612588
Inventors:
Jerrold M. Olefsky - Solana Beach CA
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
G01N 3350, G01N 3368
US Classification:
435 721
Abstract:
A screening method for identifying compositions which affect the binding of protein tyrosine phosphatase 1B (PTP1B) to phosphorylated insulin receptor is provided. This method measures a composition's ability to inhibit binding of PTP1B to the. beta. -subunit of the insulin receptor rather than phosphatase activity in general. Also provided are specific phosphopeptides which affect the binding of protein tyrosine phosphatase 1B (PTP1B) to phosphorylated insulin receptor.
Methods Of Identifying Compounds For Producing Insulin Sensitization
US Patent:
7749720, Jul 6, 2010
Filed:
Jun 17, 2005
Appl. No.:
11/570864
Inventors:
Jerrold M. Olefsky - Solana Beach CA, US
Isao Usui - Toyama, JP
Takeshi Imamura - San Diego CA, US
Isao Usui - Toyama, JP
Takeshi Imamura - San Diego CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
G01N 33/53, G01N 33/00
US Classification:
435 78, 435 71, 435 76, 435 772, 435 792
Abstract:
The invention herein provides a mode of treating metabolic syndrome, which includes Type 2 diabetes mellitus and insulin resistance in human and other subjects by identifying and administering an insulin sensitizing compound which modulates GRK2 function in the insulin signaling pathway. The invention also provides polynucleotides, polypeptides, vectors, cells, tissues and organisms useful in the identification and treatment of metabolic syndrome. A number of desirable insulin sensitizing aspects are achieved by various embodiments of the present invention.
Diabetes Treatment Methods And Drug Targets Therefor
US Patent:
8420612, Apr 16, 2013
Filed:
Jan 22, 2007
Appl. No.:
11/625795
Inventors:
Kenneth Chien - Cambridge MA, US
Lisa Lesniewski - Boulder CO, US
Jerrold Olefsky - Solana Beach CA, US
Mohammad Pashmforoush - Los Angeles CA, US
Lisa Lesniewski - Boulder CO, US
Jerrold Olefsky - Solana Beach CA, US
Mohammad Pashmforoush - Los Angeles CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 48/00, C12N 15/11, A01N 63/00, C12N 15/00, C12N 5/00, C12N 5/071
US Classification:
514 44R, 424 931, 424 932, 424 9371, 4353201, 435325, 435372, 514 44 A
Abstract:
Provided are methods of treating insulin resistance or type II diabetes. Disrupting CAP in the macrophage can alter the inflammatory response associated with impaired insulin action and ultimately result in improved insulin action in target tissues. One aspect of the invention involves administering a CAP antagonist to a patient afflicted with insulin resistance or type II diabetes in an amount sufficient to improve insulin action in target tissues.
Treatment Of Insulin Resistance
US Patent:
2003021, Nov 13, 2003
Filed:
Jan 28, 2003
Appl. No.:
10/353812
Inventors:
Jerrold Olefsky - Solana Beach CA, US
Tahir Pillay - San Diego CA, US
Tahir Pillay - San Diego CA, US
Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
International Classification:
G01N033/53, C07H021/04, C12P021/02, C12N005/06, C12N009/12, A61K048/00
US Classification:
435/007100, 435/069100, 435/194000, 435/320100, 435/325000, 514/044000, 536/023200
Abstract:
Methods and compositions are provided for the treatment of insulin-resistance through the inhibition of protein kinase C-mediated phosphorylation of the amino acid residue Serof the insulin receptor. Methods for testing candidate compounds suitable for inhibition of serine-phosphorylation by protein kinase C are also provided.